BR112022001800A2 - Plataformas e métodos de nanopartículas multivalentes e multi-específicas - Google Patents

Plataformas e métodos de nanopartículas multivalentes e multi-específicas

Info

Publication number
BR112022001800A2
BR112022001800A2 BR112022001800A BR112022001800A BR112022001800A2 BR 112022001800 A2 BR112022001800 A2 BR 112022001800A2 BR 112022001800 A BR112022001800 A BR 112022001800A BR 112022001800 A BR112022001800 A BR 112022001800A BR 112022001800 A2 BR112022001800 A2 BR 112022001800A2
Authority
BR
Brazil
Prior art keywords
nanocage
multivalent
methods
monomer
nanoparticle platforms
Prior art date
Application number
BR112022001800A
Other languages
English (en)
Portuguese (pt)
Inventor
Bebhinn Treanor
Rujas Diez Edurne
Jean-Philippe Julien
Tiantian Zhao
Original Assignee
Governing Council Univ Toronto
Hospital For Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Governing Council Univ Toronto, Hospital For Sick Children filed Critical Governing Council Univ Toronto
Publication of BR112022001800A2 publication Critical patent/BR112022001800A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
BR112022001800A 2019-08-01 2020-07-31 Plataformas e métodos de nanopartículas multivalentes e multi-específicas BR112022001800A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962881899P 2019-08-01 2019-08-01
PCT/CA2020/051061 WO2021016724A1 (en) 2019-08-01 2020-07-31 Multi-valent and multi-specific nanoparticle platforms and methods

Publications (1)

Publication Number Publication Date
BR112022001800A2 true BR112022001800A2 (pt) 2022-04-12

Family

ID=74228187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001800A BR112022001800A2 (pt) 2019-08-01 2020-07-31 Plataformas e métodos de nanopartículas multivalentes e multi-específicas

Country Status (10)

Country Link
US (1) US20230145060A1 (https=)
EP (1) EP4007779A4 (https=)
JP (2) JP2022543070A (https=)
KR (1) KR20220107151A (https=)
CN (3) CN121449754A (https=)
AU (1) AU2020320459A1 (https=)
BR (1) BR112022001800A2 (https=)
CA (1) CA3149320A1 (https=)
MX (1) MX2022001387A (https=)
WO (1) WO2021016724A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021050527A1 (en) * 2019-09-09 2021-03-18 The Regents Of The University Of California Compositions and methods for making and using multispecific antibodies
CN117157328A (zh) * 2021-01-28 2023-12-01 儿童医院 Multabody构建体、组合物和方法
US20250276070A1 (en) * 2021-07-12 2025-09-04 The Hospital For Sick Children Optimized multabody constructs, compositions, and methods
KR20240101550A9 (ko) * 2021-09-13 2025-12-10 더 호스피탈 포 식 칠드런 암 치료용 dr5-표적화 다중체
CN118488971A (zh) * 2021-09-13 2024-08-13 儿童医院 优化的Multabody构建体、组合物和方法
WO2023060358A1 (en) * 2021-10-16 2023-04-20 The Hospital For Sick Children Modified multabody constructs, compositions, and methods
EP4416189A4 (en) * 2021-10-16 2025-08-27 Hospital For Sick Children MODIFIED MULTIBODY CONSTRUCTS, COMPOSITIONS AND METHODS TARGETING SARS-CoV-2
KR20240043842A (ko) * 2022-09-27 2024-04-04 크리포 주식회사 주요 아미노산이 전하성 아미노산으로 구성된 펩타이드 태그를 포함하여 자가 조립체를 형성하는 융합 단백질 및 이를 이용하여 재조합 단백질을 정제하는 방법
KR20240043840A (ko) * 2022-09-27 2024-04-04 크리포 주식회사 주요 아미노산이 전하성 및 극성 아미노산으로 구성된 펩타이드 태그를 포함하여 자가 조립체를 형성하는 융합 단백질 및 이를 이용하여 재조합 단백질을 정제하는 방법
KR102946895B1 (ko) * 2022-10-21 2026-04-02 충남대학교산학협력단 SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도
EP4628095A1 (en) * 2022-11-07 2025-10-08 Xiamen University Fusion protein and granulated antigen comprising same
AU2023407259A1 (en) * 2022-12-18 2025-06-26 Radiant Biotherapeutics Inc. Multivalent and multispecific cytokine antagonists
KR20250143754A (ko) * 2022-12-18 2025-10-02 래디언트 바이오테라퓨틱스 인크. 다가 조혈 세포 인게이저 또는 활성화제
CN115819626B (zh) * 2022-12-23 2026-04-28 北京吉诺卫生物科技有限公司 重组铁蛋白纳米颗粒及其制备方法
EP4642797A1 (en) * 2022-12-28 2025-11-05 BioNTech SE Rna compositions targeting hiv
WO2024254514A1 (en) * 2023-06-08 2024-12-12 The University Of North Carolina At Chapel Hill Engineered antibody fusion proteins with modulable binding constants and their applications
WO2025054730A1 (en) * 2023-09-13 2025-03-20 The Hospital For Sick Children Hiv-1-targeted multabody constructs, compositions, and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659187A (zh) * 2002-05-10 2005-08-24 新世纪药品有限公司 融合铁蛋白在疫苗和其他方面的应用
KR20160094550A (ko) * 2015-01-30 2016-08-10 동국대학교 산학협력단 단일사슬항체조각과 페리틴을 포함하는 융합단백질 및 그의 용도
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY

Also Published As

Publication number Publication date
WO2021016724A1 (en) 2021-02-04
CA3149320A1 (en) 2021-02-04
CN121203033A (zh) 2025-12-26
CN114867754A (zh) 2022-08-05
EP4007779A1 (en) 2022-06-08
US20230145060A1 (en) 2023-05-11
AU2020320459A1 (en) 2022-03-03
JP2026004351A (ja) 2026-01-14
KR20220107151A (ko) 2022-08-02
JP2022543070A (ja) 2022-10-07
EP4007779A4 (en) 2023-09-06
CN121449754A (zh) 2026-02-03
MX2022001387A (es) 2022-06-08

Similar Documents

Publication Publication Date Title
BR112022001800A2 (pt) Plataformas e métodos de nanopartículas multivalentes e multi-específicas
CO2020001220A2 (es) Compuestos, composiciones y métodos
EP3506886A4 (en) HIGH-CONCENTRATED LOW VISCOUS MASP-2-INHIBITORY ANTIBODY FORMULATIONS, KITS AND METHODS
CO2017012893A2 (es) Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
BR112021022514A2 (pt) Conjugados de anticorpo e fármaco
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
BR112017011922A2 (pt) composição de suspensão de liberação prolongada gastrorretentiva, processo de preparação de uma composição, uso de uma base de suspensão
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
MX2023002379A (es) Proteinas de fusion de union a dr5 multivalentes y multiespecificas.
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
BR112014032419A2 (pt) polímero a base de etileno, composição, artigo e processo para formar o polímero a base de etileno
BR112015020663A2 (pt) composição de unha artificial, unha artificial, método para formar unha artificial, e kit de unha da técnica
MX2017002835A (es) Composicion termoplastica aplicada en caliente de alto contenido de poliamida.
AR109685A1 (es) Composiciones de nanopartículas y métodos para fabricarlas y usarlas
PE20181176A1 (es) Composiciones biofarmaceuticas
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CO2017011546A2 (es) Adhesivos acrílicos en emulsión
MX385109B (es) Formulaciones de anticuerpos.
GT200800303A (es) Combinacion anti-retroviral
BR112016015218A2 (pt) microrganismo com capacidade melhorada de produção de l-treonina e método para produzir l-treonina com o uso desse
EP4037659C0 (en) PHARMACEUTICAL COMPOSITION CONTAINING ENZALUTAMIDE
EP4069207A4 (en) PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF RIOCIGUAT
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
BR112016022117A2 (pt) Método de produção de um polímero ramificado, polímero ramificado e usos de tal polímero

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) ; THE HOSPITAL FOR SICK CHILDREN (CA)